Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Phase 2 Completed 204 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.

Timeline

Start: 2009-03-31
Primary completion: 2009-11-30
Completion: 2009-12-31

Publications

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ceftazidime	Small molecule	—	Intravenous
Comparator	Meropenem	Small molecule	—	Intravenous
Subject	Metronidazole	Small molecule	—	Intravenous
Subject	avibactam	Small molecule	—	Intravenous

Indications

No indication recorded.